BioCentury | Sep 14, 2018
Finance

Coda’s chemogenetic control

Coda Biotherapeutics Inc. could have first-mover potential in the chemogenetics space, and with a newly raised $19 million series A round, the company will move its first program toward the clinic. Seed investors MPM Capital...
BC Week In Review | Sep 14, 2018
Financial News

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...
BC Extra | Sep 12, 2018
Financial News

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...
BC Extra | Aug 9, 2018
Company News

Management tracks: Grail, Celyad, Hua

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Hal Barron and Hans Bishop to its board. Barron is CSO and president of R&D at GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), and Bishop was president and CEO...
BC Week In Review | Apr 27, 2018
Company News

Orexigen accepts $75M stalking horse bid

On April 23, Orexigen Therapeutics Inc. (NASDAQ:OREX) accepted a $75 million cash bid from an investor group including Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) to acquire Orexigen assets including worldwide rights to obesity drug Contrave naltrexone/bupropion....
BC Week In Review | Mar 16, 2018
Financial News

Orexigen files for bankruptcy

Orexigen Therapeutics Inc. (NASDAQ:OREX) said on March 12 it filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware and plans to pursue an auction sale of substantially all of...
BC Innovations | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
BC Extra | May 9, 2017
Politics & Policy

PhRMA revises eligibility criteria, cutting membership

In an update to its eligibility criteria, PhRMA will now require companies to meet benchmarks in R&D spending to be members. Companies must spend at least 10% of global sales on R&D and spend at...
BC Extra | Sep 13, 2016
Top Story

Competing drug pricing visions aired

On Tuesday, a group of six biotech CEOs and a generic drug industry advocate outlined competing visions to address controversies over the price of prescription drugs. In a commentary posted on Forbes , the CEO group...
BC Week In Review | Sep 5, 2016
Company News

Orexigen, Valeant Pharmaceuticals deal

Orexigen’s Orexigen Therapeutics Ireland Ltd. subsidiary granted Valeant’s Valeant Canada L.P. subsidiary exclusive rights to develop and commercialize obesity drug Contrave naltrexone/bupropion in Canada. Valeant said it plans to submit an NDA in Canada by...
Items per page:
1 - 10 of 371
BioCentury | Sep 14, 2018
Finance

Coda’s chemogenetic control

Coda Biotherapeutics Inc. could have first-mover potential in the chemogenetics space, and with a newly raised $19 million series A round, the company will move its first program toward the clinic. Seed investors MPM Capital...
BC Week In Review | Sep 14, 2018
Financial News

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...
BC Extra | Sep 12, 2018
Financial News

MPM, Versant launch gene therapy play Coda

Coda Biotherapeutics Inc. (South San Francisco, Calif.) debuted with a $19 million series A round led by seed investors MPM Capital and Versant Ventures. New investors Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) also...
BC Extra | Aug 9, 2018
Company News

Management tracks: Grail, Celyad, Hua

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Hal Barron and Hans Bishop to its board. Barron is CSO and president of R&D at GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), and Bishop was president and CEO...
BC Week In Review | Apr 27, 2018
Company News

Orexigen accepts $75M stalking horse bid

On April 23, Orexigen Therapeutics Inc. (NASDAQ:OREX) accepted a $75 million cash bid from an investor group including Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) to acquire Orexigen assets including worldwide rights to obesity drug Contrave naltrexone/bupropion....
BC Week In Review | Mar 16, 2018
Financial News

Orexigen files for bankruptcy

Orexigen Therapeutics Inc. (NASDAQ:OREX) said on March 12 it filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware and plans to pursue an auction sale of substantially all of...
BC Innovations | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
BC Extra | May 9, 2017
Politics & Policy

PhRMA revises eligibility criteria, cutting membership

In an update to its eligibility criteria, PhRMA will now require companies to meet benchmarks in R&D spending to be members. Companies must spend at least 10% of global sales on R&D and spend at...
BC Extra | Sep 13, 2016
Top Story

Competing drug pricing visions aired

On Tuesday, a group of six biotech CEOs and a generic drug industry advocate outlined competing visions to address controversies over the price of prescription drugs. In a commentary posted on Forbes , the CEO group...
BC Week In Review | Sep 5, 2016
Company News

Orexigen, Valeant Pharmaceuticals deal

Orexigen’s Orexigen Therapeutics Ireland Ltd. subsidiary granted Valeant’s Valeant Canada L.P. subsidiary exclusive rights to develop and commercialize obesity drug Contrave naltrexone/bupropion in Canada. Valeant said it plans to submit an NDA in Canada by...
Items per page:
1 - 10 of 371